Anti-TFPI Antibody for Hemophilia

Jen Schroeder, MD, PhD

Anti-tissue factor pathway inhibitor (anti-TFPI) antibody BAY-1093884 is being developed by Bayer Healthcare Pharmaceuticals to treat hemophilia. In this interview with Rare Disease Report during the 57th ASH Annual Meeting, Jen Schroeder, MD, PhD, of Bayer talks about the preclinical studies presented at the ASH meeting that has compelled the company to begin a phase 1 study.


Printer Printing...